Does reduced thyroid hormone action raise LDL cholesterol?

Reduced thyroid hormone action is a clinical hallmark of impaired lipid metabolism, frequently driving elevated serum cholesterol levels. This systemic shift is mediated by a direct disruption in hepatic clearance pathways.

Mechanistic pathways

• Transcriptional suppression: Thyroid hormone (primarily T3) directly stimulates low-density lipoprotein receptor (LDLR) transcription by binding to the TR-RXR heterodimer on promoter thyroid hormone response elements (TREs). It also transcriptionally upregulates SREBP-2, which binds to the sterol regulatory element in the LDLR promoter. Reduced thyroid hormone action suppresses both TRE- and SREBP-2-driven transcription, markedly reducing hepatic LDLR expression.
• Accelerated receptor degradation: Lowered thyroid action and accompanying elevated thyroid-stimulating hormone (TSH) increase the expression of PCSK9. This protein binds to cell-surface LDLRs and targets them for lysosomal degradation, further depleting the population of active receptors.

Clinical and kinetic impact

• Prolonged LDL half-life: Decreased LDLR activity directly lowers the fractional catabolic rate (FCR) of LDL. While normal receptor function maintains an LDL plasma half-life of 2.5 to 3.6 days, a 50% reduction in receptor activity extends this residence time to 4 to 5 days, doubling steady-state plasma LDL-C levels.
• Increased particle production: Impaired LDLR activity also hinders the presecretory degradation of newly synthesized apolipoprotein B (apoB) in hepatocytes, compounding serum elevations by increasing overall LDL particle production.

Bottom line

• Reduced thyroid hormone action directly suppresses LDLR transcription and accelerates its degradation via PCSK9, impairing hepatic LDL clearance and driving secondary hypercholesterolemia.